Anti-CD19 Antibodies
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Zhengxing Qu, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
Claims23
A method of treating a B-cell lymphoma or leukemia comprising administering a bispecific antibody comprising:
- a) a first anti-CD19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises (i) the light chain complementarity determining region CDR sequences CDR1 of SEQ ID NO:
- 1 (KASQSVDYDGDSYLN);
- CDR2 of SEQ ID NO:
- 17 (DASNLVS);
- and CDR3 of SEQ ID NO:
- 18 (QQSTEDPWT);
- (ii) the heavy chain CDR sequences CDR1 of SEQ ID NO:
- 19 (SYWMN);
- CDR2 of SEQ ID NO:
- 20 (QIWPGDGDTNYNGKFKG) and CDR3 of SEQ ID NO:
- 21 (RETTTVGRYYYAMDY), and (iii) human antibody framework (FR) and constant region sequences with one or more framework region amino acid residues substituted from the corresponding framework region sequences of the parent murine antibody, wherein said substituted FR residues comprise the substitution of serine for phenylalanine at Kabat residue 91 of the heavy chain variable region;
- and
- b) a second antibody or humanized antibody or antigen-binding fragment thereof.
Dependencies are inferred from the claim text.